Weight Changes After Incretin-mimetics

Starting soon · Not applicable

Conditions studied: Obesity and Obesity-related Medical Conditions

In brief

The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?

Key facts

Study ID

NCT06795360

Run by

Medical College of Wisconsin

People needed

52

Starts

2026-12-01

Expected to finish

2031-11-30

Last updated by the study team

2026-02-24

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults 18 years or older
• men and women
• prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse
• any ethnicity

You may not qualify if…

• weight > or = 400 lb
• type 1 or type 2 diabetes
• patients taking steroid medications
• anemia
• heart disease
• advanced kidney disease (CKD stage 4 and 5)
• decompensated liver disease
• hyperthyroidism
• untreated hypothyroidism
• active cancer
• post solid organ or bone marrow transplant
• HIV/AIDS
• pregnancy/plan for pregnancy in the next 6 months
• breastfeeding
• post-menopausal women
• current smoker
• current recreational drug use
• night shift or rotating shift workers

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.